Unrelated donor (UD) transplantation is the only potentially curative therapy for many leukaemia patients but is associated with a high mortality and morbidity. We sought to identify factors that could be optimised to improve outcome following UD transplantation in adults. Data was retrospectively analysed on 55 patients sequentially receiving UD transplants for CML or acute leukaemia (AL), all of whom received serotherapy for the prevention of GVHD and rejection. All patients received standard conditioning regimens. The first 28 patients transplanted also received combined pre-and post-transplant serotherapy with Campath 1G (days ؊5 to ؉5) and standard dose CsA plus MTX as GVHD prophylaxis (protocol 1). The subsequent 27 patients received a 5-day course of pre-transplant serotherapy alone either with ATG (CML patients) or Campath 1G (AL patients) on days ؊5 to ؊1 inclusive, with highdose CSA plus MTX (protocol 2). The incidence of acute GVHD was low with no patient receiving either protocol developing Ͼgrade 2 disease. The use of protocol 2 and the administration of a bone marrow cell dose above the median (2.17 ؋ 10 8 /kg) were the most important factors predicting engraftment (P ‫؍‬ 0.03 and P ‫؍‬ 0.001, respectively) but this only remained significant for cell dose in multivariate analysis (P ‫؍‬ 0.03). Overall survival for the group was 45% at 3 years and was influenced by both age (P ‫؍‬ 0.02) and disease status at transplantation (P ‫؍‬ 0.001). Receiving a cell dose above the median was also associated with a trend towards better survival (P ‫؍‬ 0.08), due primarily to a reduction in the TRM to 8.2% compared with 54.5% in those receiving a lower cell dose (P ‫؍‬ 0.002). We conclude that pretransplant serotherapy alone is highly effective at preventing acute GVHD following UD BMT and that additional post-transplant serotherapy does not confer any benefit. Furthermore, a high marrow cell dose infused has a major effect in reducing transplant- 
Allogeneic transplantation is now recognised as the only potentially curative therapy for patients with chronic myeloid leukaemia (CML) or acute leukaemia (AL) who have failed to sustain remission with standard chemotherapy regimens, or who have adverse biological features of their disease. [1] [2] [3] Although only a third of patients have an HLA-identical sibling donor, searches of the national and international registries of volunteer donors can now identify a suitable matched donor in up to 70% of cases. 4 Indeed, allogeneic transplantation from an HLA-compatible unrelated donor has now become an established treatment for young patients with CML or advanced or poor risk acute leukaemia, 5 who lack a sibling donor. However, the results of such transplants remain inferior compared to those from sibling donors, at least in adults, since they are associated with a higher mortality and morbidity due primarily to higher rates of graft failure, infection and GVHD. [6] [7] [8] [9] [10] Thus in adults undergoing unrelated donor BMT for CML an incidence of 77% grade II-IV acute GVHD has been reported using CsA and MTX for GVHD prophylaxis. 11 Factors known to influence the outcome following unrelated donor BMT include the degree of HLA matching of donor and recipient, 6, [12] [13] [14] [15] patient age and the disease status at the time of transplantation. 9, 11, 16 This information has led to the introduction of routine molecular HLA class II typing of donor and recipient pairs, and the transplantation of patients earlier in the course of their disease. CMV disease is known to be a major cause of morbidity and mortality following unrelated donor transplantation, 17, 18 resulting in the selection of CMV negative donors where possible, and the introduction of CMV prophylaxis or pre-emptive therapy policies. 19, 20 Recent evidence suggests that, perhaps due to the implementation of these measures, the results of unrelated donor BMT have significantly improved over the past decade and that the difference in overall survival between recipients of matched unrelated and sibling donor transplant has narrowed. 11 We sought to determine whether any other factors could be optimised to improve outcome further following unrelated donor transplantation for leukaemia by analysing a cohort of 55 patients sequentially undergoing unrelated donor transplantation at our centre. Two factors were identified which appeared to have a major impact on outcome, namely the scheduling of serotherapy used to prevent rejection and GVHD and the bone marrow cell dose received.
Methods

Patients
A cohort of 55 consecutive adult patients undergoing allogeneic bone marrow transplantation from volunteer unrelated donors between November 1992 and December 1998 for acute leukaemia (n = 25) or chronic myeloid leukaemia (n = 30) at our centre were studied. Thirty-seven patients were male and 18 were female with a median age of 33 years (range 16-50 years). Of the 30 CML patients, 19 were in chronic phase and were considered to be 'standard risk', whilst 11 patients were in accelerated phase or blast crisis and were considered to be 'poor risk'. Similarly of the 25 acute leukaemia patients, 18 were in CR at the time of transplant (CR1 = 5; CR2 = 10; CR3 = 3) and were considered to be 'standard risk', whilst seven were in relapse at the time of transplant and were considered to be 'poor risk'. The five patients undergoing unrelated donor transplants in CR1 either had initial refractory disease (n = 3) or poor risk features (two patients with Ph+ve ALL). Full details of patient characteristics are shown in Table 1 .
All patients received unmanipulated bone marrow grafts and the median cell dose was 2.17 ϫ 10 8 /kg (range 0.86-4.66 ϫ 10 8 /kg). Until 1995, HLA typing was performed using serological methods only, whilst thereafter the routine use of high resolution molecular methods for DR typing was introduced. All but eight patients received grafts from fully HLA-matched donors, seven of whom were transplanted from donors mismatched at a single HLA locus whilst one patient received a two-antigen mismatched graft.
Conditioning regimens and GVHD prophylaxis
All patients received standard conditioning therapy with fractionated total body irradiation (14.4 Gy in six fractions The first 28 patients transplanted received combined preand post-transplant serotherapy using Campath 1G anti-CD52 antibody (10 mg/day from days Ϫ5 to +4 inclusive) according to the Campath Users Consensus Protocol. GVHD prophylaxis in this group was with standard dose CSA (1.5 mg/kg twice daily starting 36 h pre-transplant) and short course methotrexate (MTX) on days +2, +4, +8 and +12 (8 mg/m 2 ) (protocol 1). In 1996 this regimen was changed and the subsequent 27 patients instead received pre-transplant serotherapy alone, either as a short course of rabbit ATG (Thymoglobuline; Institute Merieux, Lyon, France: 150 mg on days Ϫ5 to Ϫ1 inclusive) (CML patients), or Campath 1G (10 mg on days Ϫ5 to Ϫ1 inclusive) (acute leukaemia patients). These patients also received initial 'high-dose' CsA (2.5 mg/kg twice daily from day Ϫ1 to day +1) then reducing to 1.5 mg/kg twice daily and a short course of MTX (15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6 and +11) for GVHD prophylaxis (protocol 2). 21 Cyclosporin A was commenced 36 h prior to the transplant and was continued intravenously until the patient could tolerate oral CsA which was usually between day +13 and day +20. Oral CsA was introduced at an initial dose of 6.25 mg/kg 12 hourly. CsA levels were measured twice weekly using peripheral venous samples and dosage was adjusted to maintain a whole blood trough level of 95-200 ng/ml for protocol 1 patients and 200-300 ng/ml for patients receiving protocol 2. 21 This dose was continued until day +100 and then slowly tapered. The first trough level of CsA was measured on day +1 post transplant and if the level was subtherapeutic the dose was increased to maintain the level within the target range.
Supportive therapy
All patients were nursed in isolation rooms with air filtration. Irradiated blood products were used for all patients and CMV negative blood products were used for CMV negative recipients with CMV negative donors. Antimicrobial prophylaxis for selective gut decontamination and antifungal agents were used for all patients according to local policies which varied over the years. All patients who were CMV positive or who received CMV positive grafts were treated with high-dose i.v. acyclovir (10 mg/kg three times daily). Neutropenic sepsis was treated with broad spectrum antibiotics according to local policies with the addition of amphotericin B at 48 h. A pre-emptive CMV treatment policy using gancyclovir was introduced in 1996 for patients shown to have reactivated CMV based on weekly CMV PCR and antigenaemia screening results. Haemopoietic growth factors were given to the majority of patients starting between day 7 and day 10 post transplant.
Statistical methods
The
2 and rank sum test were used for statistical analyses and Kaplan-Meier plots for time-dependent analyses of survival, transplant-related mortality and relapse. Cox regression and logistic regression analyses were used for multivariate analysis.
Outcome measures
The outcomes measured were the rates of engraftment and graft failure, transplant-related mortality, GVHD, relapse, survival and leukaemia-free survival.
Engraftment was considered to have occurred when the absolute neutrophil count had reached 0.5 ϫ 10 /l for at least 3 consecutive days after initial engraftment.
Transplant-related mortality was defined as death in continuous complete remission. Acute and chronic GVHD were diagnosed and graded according to standard criteria 22, 23 with only those patients who survived for greater than 100 days being evaluated for chronic GVHD.
Relapse was defined as Ͼ5% blasts in the marrow posttransplant for the acute leukaemia patients, and for the CML patients relapse was defined as haematological evidence of recurrent leukaemia, the presence of the Philadelphia chromosome on cytogenetic analysis or the presence of bcr-abl transcripts by RT-PCR analysis.
Results
Engraftment
Eleven of 53 evaluable patients (20.7%) experienced primary graft failure, of whom two remain alive following either autologous reinfusion (one patient) or following a successful second unrelated donor transplant from an alternative donor (one patient). The remaining 42 patients achieved sustained donor engraftment with a median time to neutrophils Ͼ0.5 ϫ 10 9 /l of 18 days post transplant (range 12-75).
The only factors found to influence engraftment significantly were the conditioning regimen used and the bone marrow cell dose received (Tables 2 and 3 ). The use of Table 2 Outcome depending on cell dose received protocol 2 gave an odds ratio for engraftment of 6.35 (95% CI 1.2-33.1) with only two of 27 (7%) patients having graft failure, compared to nine out of 28 (32%) patients receiving protocol 1 (P = 0.03). Receiving a bone marrow cell dose above the median (2.17 ϫ 10 8 /kg ) was also associated with a higher rate of engraftment, giving an odds ratio of 15.6 (95% CI 1.8-134) since only one out of 27 patients (3.7%) receiving a high cell dose failed to engraft, compared to 10 out of 27 patients (37%) receiving a low cell dose (P = 0.01). These two factors were found to confound each other since following the switch to protocol 2, a higher marrow cell dose has been more regularly obtained. Thus in multivariate analysis only receiving a cell dose above the median remained a significant predictor for engraftment (P = 0.03).
The risk of graft failure also appeared to be influenced by the underlying diagnosis, since this occurred in nine of 30 (30%) CML patients compared to only two of 25 (8%) patients with acute leukaemia, although this did not reach statistical significance (P = 0.08). The degree of HLA matching was not shown to be a factor predicting engraftment, since all but one of the eight patients with mismatched donors engrafted. However, it is of interest to note that protocol 2 was used as the conditioning regimen for six of the seven mismatched patients who engrafted.
Transplant-related mortality
Sixteen patients have died of transplant-related causes giving a 3-year cumulative transplant-related mortality of 37%. All these events occurred within the first 100 days post transplant with no late deaths being seen. Graft rejection was the major causative factor in eight of these 16 early deaths (50%) and five of the remaining deaths were due to infection (two of which were CMV related, prior to the introduction of screening and pre-emptive therapy), whilst two patients died due to the development of TTP. One patient, with known impaired left ventricular function, died of cardiac failure on day 12 post transplant. No patient had GVHD as a contributory factor in the cause of death.
The only factor shown to reduce the risk of nonleukaemic death was receiving a cell dose above the median (P = 0.0022). The TRM for this group was 8.2% at 3 years as compared to 59% for the low cell dose patients ( Figure  1 ), and this effect on TRM remained even when only the standard risk patients were considered (P = 0.008). The effect of cell dose on TRM risk was also found to be significant in a multivariate analysis incorporating patient age, disease status and conditioning protocol used (P = 0.01).
Bone Marrow Transplantation
GVHD
A low rate of both acute and chronic GVHD was seen in this study. Of the 40 evaluable patients, grade I acute GVHD was seen in seven patients, two patients developed grade II GVHD and no patient developed greater than grade II GVHD. Limited chronic GVHD subsequently occurred in three out of 26 evaluable patients and no patient has had a GVHD-related death. No effect of cell dose or the protocol used was seen with respect to the incidence of GVHD.
Relapse and leukaemia-free survival
Fifteen patients have relapsed post transplant giving a cumulative relapse rate of 44.7% with a median onset at 7 months (range 1-24 months). Neither the marrow cell dose received nor the conditioning protocol used were associated with relapse risk post transplant (see Tables 2 and 3 ). Disease status at transplantation was the only factor shown to be associated with a lower risk of relapse since only four of 37 (10.8%) standard risk patients relapsed compared to 11 of 18 (61%) poor risk patients (P Ͻ 0.00001). This was true for patients with acute leukaemia and those with CML. No patient transplanted with overt relapsed acute leukaemia has survived disease-free.
For patients with CML, molecular minimal residual disease monitoring post transplant has been routinely undertaken at 3 monthly intervals since 1995, using RT-PCR for bcr-abl transcripts. Two patients relapsing after transplantation for CML have received donor leucocyte infusions and remain in cytogenetic and molecular remission at 35 and 36 months, respectively.
Overall, 24 patients remain alive and disease-free at a median follow-up of 2.5 years post transplant (range 0.25-6 years) and all these patients have Karnofsky scores of Ͼ90%.
Overall survival
Overall survival for the whole group was 45% at 3 years. As expected, univariate analysis confirmed that survival was significantly better for younger as compared to older patients (aged above or below the median) (P = 0.02) ( Figure 2 ) and for those with standard risk compared to poor risk disease (P = 0.001) (Figure 3 ). There was also a trend towards superior survival for patients receiving a cell dose above the median (2.17 ϫ 10 8 /kg) although this did not reach significance (P = 0.08) (Figure 4 ) and this was shown to be primarily due to a reduced TRM risk (see below). There was no apparent effect of protocol 2 on survival although follow up for the protocol 2 patients remains short. Following multivariate analysis, the only factor which remained significant for survival was disease status at transplantation (P = 0.02).
Discussion
This study confirms previous findings that allogeneic transplantation from an HLA-compatible donor is a feasible option for young patients with otherwise incurable leu- Kaplan-Meier graph to show the overall survival following unrelated donor bone marrow transplantation depending on patient age at transplantation. The unbroken line represents the patients who were below the median age (33 years) at the time of transplantation whereas the dotted line represents the patients who were above the median age (P = 0.02).
kaemias. Twenty-four of 55 patients remain in continuing complete remission at a median follow-up of 2.5 years and the overall survival was 45% at 3 years. As has been previously shown in other series, 9,15,16 both age and disease status at transplantation were the most important factors influencing overall survival (P = 0.02 and P = 0.001, respectively), and disease status was the only factor to significantly affect relapse risk (P Ͻ 0.00001).
In addition we observed that receiving a higher cell dose was associated with a trend to improved survival (P = 0.08). Further analysis showed that the effect of cell dose was primarily due to a reduced risk of graft failure and of other causes of non-leukaemic death. Indeed, receiving a cell dose above the median was the most important factor predicting engraftment in this series of patients, and also resulted in a reduction in the transplant-related mortality rate from 59% for those receiving a low cell dose, to 8% for those receiving a cell dose above the median (P = Time (years)
Cumulative survival Figure 4 Kaplan-Meier graph to show the overall survival following unrelated donor bone marrow transplantation depending on the bone marrow cell dose received. The unbroken line represents those patients who received a bone marrow cell dose above the median (2.17 ϫ 10 9 /kg) and the dotted line represents those patients who received a cell dose below the median (P = 0.08).
0.0022). The effects of cell dose on outcome following unrelated donor transplantation were first described by Sierra et al. 24 This group showed that following unrelated donor transplantation for acute leukaemia, a large marrow cell dose was associated with improved engraftment of granulocytes and platelets, and a reduced risk of nonleukaemic death, mainly due to a reduction in the severity of acute GVHD and a reduction in the number of deaths from infection. Hansen et al 11 have also reported a beneficial effect of higher marrow cell dose on both the speed and probability of engraftment in patients undergoing unrelated donor BMT for CML. In both these studies the median cell doses were significantly higher than that in our study at 3.65 ϫ 10 8 /kg and 3.0 ϫ 10 8 /kg, respectively.
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These differences may in part be due to the fact that our study was of an adult population whereas both those of Sierra et al and Hansen et al included a number of children. Two other studies have suggested a benefit for increased cell dose following sibling allografts, 25, 26 one of which was also associated with a reduction in severity of acute GVHD. 26 Our study confirms the impact of high cell dose on TRM following unrelated donor transplantation, but in our analysis this appeared primarily to be due to a reduced rate of rejection, with no effect on the incidence or severity of acute GVHD.
Both serotherapy regimens used in this study were associated with a very low incidence of acute GVHD, certainly much lower than that reported in patients receiving CsA and MTX alone for GVHD prophylaxis, 27 where a cumulative incidence of grade III-IV GVHD of 47% has been reported. 24 In this study no patient developed Ͼgrade II GVHD despite the fact that the scheduling of the serotherapy was very different for these two groups of patients. In protocol 1, we utilised the monoclonal anti-CD52 antibody, Campath 1G, which was given intravenously from day −5 to day +4 inclusive. CD52 is expressed abundantly on all human lymphocytes and thus the use of this antibody effectively depletes residual host T cells 28 and this regimen was intended to reduce the risk of rejection as well as to deplete donor T lymphocytes in vivo, and hence ameliorate GVHD when combined with conventional post-transplant immunosuppression with CsA and MTX. It is well known that in vitro T cell depletion effectively reduces GVHD, [29] [30] [31] [32] [33] but this benefit may be negated by an increased risk of graft rejection 34, 35 and also a higher risk of leukaemic relapse due to the loss of graft-versus-leukaemia effects of donor T lymphocytes. 36, 37 The use of additional pre-transplant immunosuppression has been shown to reduce, but not abolish, the risk of rejection for patients receiving in vitro T cell-depleted transplants. [38] [39] [40] Using protocol 1 we observed a low incidence of acute GVHD but an apparently higher rate of graft failure as compared to protocol 2 in which serotherapy was only given pre-transplant. However, this effect on engraftment may have been mainly due to the higher cell dose received by the protocol 2 group since it did not remain significant in multivariate analysis. The other major finding, however, was that the omission of post-transplant antibody therapy did not increase the risk of either acute or chronic GVHD. This may be explained by the fact that although the antibody (ATG or Campath) was only given pre-transplant it may be detectable in the serum for several days post transplant, hence giving some degree of in vivo T cell depletion. 41 However, the level of antibody available post transplant will clearly be lower than when it is administered post marrow infusion. This may result in a less profound in vivo T cell depletion, leaving some residual donor T cells in the host which may facilitate engraftment. Other groups have also demonstrated beneficial effects of pre-transplant serotherapy with either ATG or Campath 1G antibodies prior to unmanipulated unrelated donor transplants, particularly in terms of reducing the risk of GVHD. 21, [42] [43] [44] [45] [46] [47] The rationale for tailoring the pre-transplant serotherapy to the disease type in protocol 2 was based on the view that polyclonal ATG may be more immunosuppressive than
Campath 1G, and hence might reduce rejection for CML patients who generally have received no prior intensive therapy, whilst the monoclonal Campath 1G antibody would be suitable for acute leukaemia patients most of whom had undergone recent chemotherapy (often including fludarabine in the 'FLAG' regimen 48 ). Furthermore the CD52 antigen is known to be highly expressed in several leukaemias including 70% or more of adult ALL and hence Campath 1G may have an additional anti-tumour effect in acute leukaemia. 49 In summary, we have confirmed that the outcome of unrelated donor transplantation for leukaemia in adults is critically dependent upon the number of bone marrow cells infused and that patients receiving a low cell dose are at risk of graft failure and a high transplant-related mortality. Indeed, the major effect of cell dose on improving engraftment and transplant-related mortality seen in this study provides support for the introduction of careful pilot studies of G-CSF-mobilised peripheral blood stem cells into the setting of unrelated donor transplantation, since this would consistently improve the cell dose received. 50 In addition we have shown that the administration of pretransplant serotherapy alone, when combined with posttransplant CsA and MTX is associated with a low risk of acute and chronic GVHD and results in a high engraftment rate whilst maintaining a low risk of GVHD. However, since this was a retrospective analysis and not a randomised comparison of the two protocols, further randomised studies would be required to confirm that additional post-transplant in vivo T cell depletion provides no additional benefit in the setting of unrelated donor transplantation.
